Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undoubtedly the most challenging pandemic in the current century and remains a global health emergency. As the number of COVID-19 cases in the world is on the rise and variants continue to e...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/5/1101 |
| _version_ | 1797496613570084864 |
|---|---|
| author | Cong Liu Nino Rcheulishvili Zhigao Shen Dimitri Papukashvili Fengfei Xie Ziqian Wang Xingyun Wang Yunjiao He Peng George Wang |
| author_facet | Cong Liu Nino Rcheulishvili Zhigao Shen Dimitri Papukashvili Fengfei Xie Ziqian Wang Xingyun Wang Yunjiao He Peng George Wang |
| author_sort | Cong Liu |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undoubtedly the most challenging pandemic in the current century and remains a global health emergency. As the number of COVID-19 cases in the world is on the rise and variants continue to emerge, there is an urgent need for vaccines. Among all immunization approaches, mRNA vaccines have demonstrated more promising results in response to this challenge. Herein, we designed an mRNA-based vaccine encoding the receptor-binding domain (RBD) of SARS-CoV-2 encapsulated in lipid nanoparticles (LNPs). Intramuscular (i.m.) administration of the mRNA-RBD vaccine elicited broad-spectrum neutralizing antibodies and cellular responses against not only the wild-type SARS-CoV-2 virus but also Delta and Omicron variants. These results indicated that two doses of mRNA-RBD immunization conferred a strong immune response in mice against the wild-type SARS-CoV-2, while the booster dose provided a sufficient immunity against SARS-CoV-2 and its variants. Taken together, the three-dose regimen strategy of the mRNA-RBD vaccine proposed in the present study appears to be a promising reference for the development of mRNA vaccines targeting SARS-CoV-2 variants. |
| first_indexed | 2024-03-10T03:06:06Z |
| format | Article |
| id | doaj.art-e23ce82722344906a6863b4d95821d9e |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T03:06:06Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-e23ce82722344906a6863b4d95821d9e2023-11-23T12:39:38ZengMDPI AGPharmaceutics1999-49232022-05-01145110110.3390/pharmaceutics14051101Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its VariantsCong Liu0Nino Rcheulishvili1Zhigao Shen2Dimitri Papukashvili3Fengfei Xie4Ziqian Wang5Xingyun Wang6Yunjiao He7Peng George Wang8School of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaSchool of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaSchool of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaSchool of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaSchool of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaSchool of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaSchool of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaSchool of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaSchool of Medicine, Southern University of Science and Technology, Shenzhen 518000, ChinaCoronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undoubtedly the most challenging pandemic in the current century and remains a global health emergency. As the number of COVID-19 cases in the world is on the rise and variants continue to emerge, there is an urgent need for vaccines. Among all immunization approaches, mRNA vaccines have demonstrated more promising results in response to this challenge. Herein, we designed an mRNA-based vaccine encoding the receptor-binding domain (RBD) of SARS-CoV-2 encapsulated in lipid nanoparticles (LNPs). Intramuscular (i.m.) administration of the mRNA-RBD vaccine elicited broad-spectrum neutralizing antibodies and cellular responses against not only the wild-type SARS-CoV-2 virus but also Delta and Omicron variants. These results indicated that two doses of mRNA-RBD immunization conferred a strong immune response in mice against the wild-type SARS-CoV-2, while the booster dose provided a sufficient immunity against SARS-CoV-2 and its variants. Taken together, the three-dose regimen strategy of the mRNA-RBD vaccine proposed in the present study appears to be a promising reference for the development of mRNA vaccines targeting SARS-CoV-2 variants.https://www.mdpi.com/1999-4923/14/5/1101SARS-CoV-2COVID-19mRNA vaccineRBDLNPsneutralizing antibodies |
| spellingShingle | Cong Liu Nino Rcheulishvili Zhigao Shen Dimitri Papukashvili Fengfei Xie Ziqian Wang Xingyun Wang Yunjiao He Peng George Wang Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants Pharmaceutics SARS-CoV-2 COVID-19 mRNA vaccine RBD LNPs neutralizing antibodies |
| title | Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants |
| title_full | Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants |
| title_fullStr | Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants |
| title_full_unstemmed | Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants |
| title_short | Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants |
| title_sort | development of an lnp encapsulated mrna rbd vaccine against sars cov 2 and its variants |
| topic | SARS-CoV-2 COVID-19 mRNA vaccine RBD LNPs neutralizing antibodies |
| url | https://www.mdpi.com/1999-4923/14/5/1101 |
| work_keys_str_mv | AT congliu developmentofanlnpencapsulatedmrnarbdvaccineagainstsarscov2anditsvariants AT ninorcheulishvili developmentofanlnpencapsulatedmrnarbdvaccineagainstsarscov2anditsvariants AT zhigaoshen developmentofanlnpencapsulatedmrnarbdvaccineagainstsarscov2anditsvariants AT dimitripapukashvili developmentofanlnpencapsulatedmrnarbdvaccineagainstsarscov2anditsvariants AT fengfeixie developmentofanlnpencapsulatedmrnarbdvaccineagainstsarscov2anditsvariants AT ziqianwang developmentofanlnpencapsulatedmrnarbdvaccineagainstsarscov2anditsvariants AT xingyunwang developmentofanlnpencapsulatedmrnarbdvaccineagainstsarscov2anditsvariants AT yunjiaohe developmentofanlnpencapsulatedmrnarbdvaccineagainstsarscov2anditsvariants AT penggeorgewang developmentofanlnpencapsulatedmrnarbdvaccineagainstsarscov2anditsvariants |